FOR AUTHORS
Search
Search Results
##search.searchResults.foundPlural##
-
S13:6 | Investigating the intricate interplay between pulmonary functionality and advanced microangiopathy in very early diagnosis of systemic sclerosis Eugenio Capparelli1, Eleonora Zaccara1, Daniela Bompane1, Elisabetta Ricchiuto2, Giorgio Bonardi2, Laura Castelnovo1, Antonio Tamburello1, Antonino Mazzone3, Paola Faggioli1. | 1Rheumatology Unit; 2Pneumology Unit; 3Internal Medicine Unit, ASST Ovest Milanese, Legnano, Italy.
136 -
PO:11:162 | DRESS syndrome: a case treated with mepolizumab Alessandro Belotti Masserini1, Stefania Bertocchi1, Eleonora Bruschi1, Silvia Breda1, Valeria Rossi1, Elide Lupi1, Tania Ubiali1, Fabrizio Angeli1, Massimiliano Limonta1 | 1ASST Papa Giovanni XXIII, Bergamo, Italy
210 -
PO:16:227 | Anifrolumab for Systemic Lupus Erythematosus: Preliminary Safety and Efficacy Findings from the Italian Experience Paola Bizioli1|2, Chiara Orlandi1|2, Claudia Barison1|2, Cesare Tomasi3, Alessia Caproli1, Silvia Piantoni1|2, Simona Signorini4, Emirena Garrafa4, Cecilia Nalli1, Micol Frassi1, Ilaria Cavazzana1|2, Micaela Fredi1|2, Franco Franceschini1|2 | 1Rheumatology and Clinical Immunology Unit - ERN ReCONNET, ASST Spedali Civili of Brescia, Italy; 2Department of Clinical and Experimental Sciences, University of Brescia, Italy; 3Department of Clinical and Experimental Sciences, University of Brescia, Italy; 4Laboratory of Clinical Chemistry, Department of Molecular and Translational Medicine, University of Brescia, Italy
60 -
PO:16:241 | Prevalence and associated factors of premature ovarian insufficiency in women with systemic lupus erythematosus: the role of human herpesviruses HHV-7 and HHV-8 Margherita Rizzo1, Francesca Ruffilli1, Silvia Beltrami2, Daria Bortolotti2, Roberta Rizzo2, Carlo Garaffoni1, Ettore Silvagni1, Marcello Govoni1, Alessandra Bortoluzzi1 | 1UOC Reumatologia, Dipartimento di Scienze Mediche, Università di Ferrara e Azienda Ospedaliero-Universitaria S. Anna, Ferrara; 2Dipartimento di Scienze Chimiche, Farmaceutiche e Agrarie, Ferrara Italy
172 -
PO:14:195 | Real-world effectiveness of anifrolumab in achieving treatment targets and reducing systemic lupus erythematosus disease burden: 6-month interim analysis of the REVEAL study Chiara Cardelli1|2, Chiara Tani1, Luca Moroni3, Filippo Vesentini4, Francesca Bottazzi5, Micaela Fredi6, Ettore Silvagni7, Matteo Piga8, Flavia Riccio9, Fulvia Ceccarelli10, Ginevra De Marchi11, Edoardo Biancalana12, Gianluca Moroncini13, Rita Mulè14, Mariele Gatto15, Laura Coladonato16, Paola Conigliaro17, Maria Gerosa18, Andrea Picchianti Diamanti19, Benedetta Bianchi20, Federica Maiolini20, Michela Gasparotto20, Serena Guiducci20, Maria Ilenia De Andres20, Alberto Lo Gullo20, Silvia Noviello20, On Behalf Of The Reveal Investigators20, Marta Mosca1. | 1Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa; 2Department of Medical Biotechnologies, University of Siena, Siena; 3Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS San Raffaele Hospital, Milano; 4Rheumatology Unit, Department of Medicine, University of Padua, Padova; 5Department of Internal Medicine and Therapeutics, University of Pavia, Pavia; 6Rheumatology and Clinical Immunology, Department of Clinical and Experimental Sciences, University of Brescia, Brescia; 7Section of Rheumatology, Department of Medical Sciences, University of Ferrara; AOU Sant'Anna, Ferrara; 8Rheumatology Unit, Department of Medical Sciences and Public Health, University of Cagliari, Cagliari; 9Department of Precision Medicine, University of Campania Luigi Vanvitelli, Napoli; 10Rheumatology Unit, Dept. of Clinical Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Roma; 11Division of Rheumatology, Department of Medicine, Azienda Sanitaria Universitaria del Friuli Centrale, Udine; 12Internal Interdisciplinary Medicine Unit, Department of Experimental and Clinical Medicine, University of Florence, Firenze; 13Department of Clinical and Molecular Sciences, Marche Polytechnic University, Ancona; 14Azienda Ospedaliero-Universitaria di Bologna, Internal Medicine and Rheumatology, IRCCS S. Orsola Malpighi, Bologna; 15Academic Rheumatology Centre, Department of Clinical and Biological Sciences, University of Turin; AO Mauriziano, Torino; 16Rheumatology Unit, Department of Precision and Regenerative Medicine and Ionian Area, University of Bari, Bari; 17Rheumatology, Allergology and Clinical Immunology, Department of Systems Medicine, Tor Vergata University of Rome, Roma; 18Clinical Rheumatology, ASST Gaetano Pini CTO; Department of Clinical Sciences and Community Health, University of Milano, Milano; 19Department of Clinical and Molecular Medicine, Sapienza University of Rome; AOU Sant'Andrea, Roma, Italy; 20Italian REVEAL Study Group Italy, Italy
195 -
CO:01:1 | Efficacy and safety of rituximab across the four phenotypes of IgG4-related disease: a European multi-center cohort study of 115 patients Marco Lanzillotta1, Jens Vikse2, Elisabetta Goni3, Veronica Batani1, Jasmin Mahajne1, Lorenzo Dagna1, Emanuel Della Torre1. | 1Unit of Immunology, Rheumatology, Allergy, and Rare Disease, IRCCS Ospedale San Raffaele, Milano, Italy; 2Department of Rheumatology, Stavanger University Hospital, Norway; 3Department of Medicine II, University Hospital, Ludwig Maximilian University, Munich, Germany
323 -
PO:26:087 | Rituximab versus glucocorticoids for IgG4-related disease: a European retrospective multi-center study of 167 patients Marco Lanzillotta1, Jens Vikse2, Elisabetta Goni3, Jasmin Mahajne1, Veronica Batani1, Lorenzo Dagna1, Emanuel Della-Torre1 | 1Unit of Immunology, Rheumatology, Allergy, and Rare Disease, IRCCS Ospedale san Raffaele Milano, Italy; 2Department of Rheumatology, Stavanger University Hospital, Stavanger, Norway; 3Department of Medicine II, University Hospital, Ludwig Maximilian University Munich, Munich Germany
70
